Oct 20, 2009 by Brian Orelli, PhDAll Tysabri, All the TimeBiogen needs to focus on its most potential-packed drug.
Oct 19, 2009 by Brian Orelli, PhDFoolish Forecast: A Last Look at "Mini" PfizerViews you can use to get clues on tomorrow's news.
Oct 19, 2009 by Brian Orelli, PhDStill Waiting for Its BlockbusterThe "Jeopardy" music plays while the FDA delays.
Oct 16, 2009 by Brian Orelli, PhDCongress to Insurers: Say Goodbye to Your MonopolyYou can't have both Boardwalk and Park Place.
Oct 15, 2009 by Brian Orelli, PhDThis Partnership Will Go No FurtherWyeth and Progenics call it quits.
Oct 14, 2009 by Brian Orelli, PhDConsistency Makes This Stock a WinnerAbbott turns in a solid quarter, but it needs to keep branching out.
Oct 13, 2009 by Brian Orelli, PhDHealth-Care Reform: You Can't Have It Both WaysFrank Sinatra was right: You can't have one without the other.
Oct 13, 2009 by Brian Orelli, PhDJ&J Needs to Get Drugged UpMedical devices and diagnostics pass by drugs as the main revenue source.
Oct 2, 2009 by Brian Orelli, PhDWarning: Potential Blockbuster AheadIt'll enter a crowded market, but there's plenty to go around.
Oct 2, 2009 by Brian Orelli, PhDA Plasma-tastic IPOThe health-care IPO market is open for a select few.
Oct 1, 2009 by Brian Orelli, PhDGeez, Lighten Up, Mr. Market!Investors dish out undue punishment to Onyx.
Sep 30, 2009 by Brian Orelli, PhDThis IPO Is SluggishIs it just a little cold or something more serious?
Sep 30, 2009 by Brian Orelli, PhDCall Me a Wimp, but I'm Still NervousCan the mud Sequenom seems to be running in turn to quicksand?
Sep 30, 2009 by Brian Orelli, PhDBigger Size, Lower ReturnsHistory is not on Merck and Schering's side.
